NCT03257163View on ClinicalTrials.gov

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Epstein-Barr Virus PositiveGastric AdenocarcinomaMismatch Repair Protein DeficiencyStage IB Gastric Cancer AJCC v7Stage II Gastric Cancer AJCC v7Stage IIA Gastric Cancer AJCC v7Stage IIB Gastric Cancer AJCC v7Stage III Gastric Cancer AJCC v7Stage IIIA Gastric Cancer AJCC v7Stage IIIB Gastric Cancer AJCC v7Stage IIIC Gastric Cancer AJCC v7
Interventions
DRUG

Capecitabine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (4)

10467

Montefiore Medical Center, The Bronx

30308

Emory University, Atlanta

08690

RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER